About UsMembershipMarketplaceResourcesGlobal Business Atlas
Top AI CompaniesTop Blockchain Influencers & AuthorsTop Global Digital AgenciesBusinessabc Country IndexesTop Accelerators and Chambers of CommerceTop Public Companies by MarketcapBusinessabc Education IndexesTop Malaysian Companies
DirectoryCompaniesLeadersInvestorsUniversitiesOrganisations
Loading wiki page…

Get Your Own Businessabc AI Visibility ID

Boost AI visibility, credibility, and discoverability

Learn More
Last Updated: 2026
Amicus Therapeutics image

Amicus Therapeutics

Rank#3451
Market Cap4.55B
CountryUnited States
Summary
History
Mission
Vision
References
Summaryarrow
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
Historyarrow

Amicus Therapeutics was founded in 2002 to develop innovative therapies for rare, devastating diseases that lack effective treatments. Over the years, the company has invested heavily in research to successfully bring new treatments to market. The company has taken a rare disease focus and has become one of the largest biotech companies in the world.

Missionarrow
Amicus Therapeutics is dedicated to discovering, developing and delivering novel, first-in-class treatments that improve and prolong the lives of individuals living with rare and devastating conditions.
Visionarrow
Amicus Therapeutics’ vision is to be the leading biotechnology company in the world, developing therapies that significantly improve the lives of people living with rare and devastating diseases.
Referencesarrow

https://en.wikipedia.org/wiki/Amicus_Therapeutics

https://in.investing.com/equities/amicus-therapeutics

https://finance.yahoo.com/quote/FOLD/profile?p=FOLD

https://www.crunchbase.com/organization/amicus-therapeutics

https://sec.report/CIK/0001178879

https://companiesmarketcap.com/

https://amicusrx.com

Share

Leadership team
M
Mr. John F. Crowley (Exec. Chairman)
M
Mr. Bradley L. Campbell M.B.A. (CEO, Pres & Director)
M
Ms. Daphne E. Quimi CPA, M.B.A. (Chief Financial Officer)
Products / Services
Biotechnology, Health Care, Pharmaceutical, Therapeutics
Number of Employees
100 - 500
Address
Cranbury, New Jersey, United States
Established
2002-01-01
Company Registration
SEC CIK number: 0001178879
Revenue
100M - 500M
Traded as
FOLD
Website
https://amicusrx.com
Social Media
linkedinfacebookx
Last Updated: 2026
Logo

Businessabc provides digital business directory, digital blockchain AI certification, resources, and marketplace for businesses, organisations, and professionals.

Contacts

Email
Contact

Follow Us

Created Produced

Partner logo
Partner logo

Tech AI Media Platforms

Partner logo
Partner logo
Partner logo
Partner logo
Partner logo
Partner logo

Copyright 2026 © Businessabc powered by

Powered by ztudium group

DisclaimerPrivacy PolicyTerms of Service
Partner logo
Partner logo
Partner logo
Partner logo
Partner logo
Partner logo